Table 1.
Laboratory findings prior to the initiation of the combination treatment with asunaprevir and daclatasvir in case 1
| Item | Value | Item | Value | Item | Value |
|---|---|---|---|---|---|
| AST | 15 IU/l | WBC | 4,500/μl | AFP | 4.6 ng/ml |
| ALT | 18 IU/l | RBC | 368 × 104/μl | PIVKA-2 | 14 mAU/ml |
| LDH | 191 IU/l | hemoglobin | 11.3 g/dl | ferritin | 426.1 ng/ml |
| ALP | 459 IU/l | hematocrit | 34.7% | TSH | 0.665 μIU/ml |
| γ-GTP | 67 IU/l | platelets | 10.9 × 104/μl | fT3 | 2.48 pg/ml |
| T.BIL | 0.5 mg/dl | PT | 120% | fT4 | 1.12 ng/dl |
| D.BIL | 0.1 mg/dl | PT-INR | 1.00 | blood sugar | 100 mg/dl |
| TP | 6.7 g/dl | anti-HCV | positive | HbA1c | 5.3% |
| Alb | 4 g/dl | HCV RNA | 4.5 log IU/ml | CRP | 0 mg/dl |
| T.CHO | 169 mg/dl | HCV genotype | 1b | ||
| UA | 7 mg/dl | HBsAg | negative | ||
| UN | 57 mg/dl | anti-HBs | negative | ||
| Cre | 2.45 mg/dl | anti-HBc | negative | ||
| eGFR | 22.9 ml/min/1.73 m2 | anti-HIV | negative |
LDH = Lactate dehydrogenase; ALP = alkaline phosphatase; γ-GTP = γ-glutamyltransferase; T.BIL = total bilirubin; D.BIL = direct bilirubin; TP = total protein; Alb = albumin; T.CHO = total cholesterol; UA = uric acid; UN = urea nitrogen; Cre = creatinine; WBC = white blood cell count; RBC = red blood cell count; PT = prothrombin time; PT-INR = PT international normalized ratio; anti-HCV = anti-HCV antibody; HBsAg = hepatitis B virus surface antigen; anti-HBs = anti-hepatitis B virus surface antibody; anti-HBc = anti-hepatitis B virus core antibody; anti-HIV = anti-human immunodeficiency virus antibody; AFP = α-fetoprotein; PIVKA-2 = protein induced by vitamin K absence-2; TSH = thyroid-stimulating hormone; fT3 = free triiodothyronine; fT4 = free thyroxine; HbA1c = hemoglobin A1c; CRP = C-reactive protein.